HAYA Therapeutics first in the TOP 100 Swiss Startup Award 2023!

HAYA Therapeutics first in the TOP 100 Swiss Startup Award 2023!

12.09.2023

Two UNIL alumni - and members of our 100 Entrepreneurs community - took first place in the TOP 100 Swiss Startup Award on 6 September 2023! Congratulations to Daniel Blessing and Samir Ounzain, who have been recognised for the potential of their company Haya Therapeutics.

Founded in 2019, this biotech company harnesses the power of the black genome to develop precise and potent RNA-based therapies to reprogram the cellular states that cause disease. In 2017, the team led by molecular biologist Samir Ounzain identified the trigger for cardiac fibrosis at Lausanne University Hospital - a long non-coding RNA (lncRNA) molecule called Wisper. On the basis of these results, co-founder Daniel Blessing has developed a personalised drug for use from 2019. This is currently in the pre-clinical phase.

Read the TOP 100 Swiss Startup Award article here.